• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4628324)   Today's Articles (52)   Subscriber (49660)
For: Pouillon L, Allocca M, Peyrin-Biroulet L. Editorial: antigenic response to CT-P13 and infliximab originator in IBD shows similar epitope recognition-evidence from basic science supports safe switching to biosimilars. Aliment Pharmacol Ther 2018;48:574-575. [PMID: 30156324 DOI: 10.1111/apt.14847] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Number Cited by Other Article(s)
1
Barbier L, Vulto AG. Interchangeability of Biosimilars: Overcoming the Final Hurdles. Drugs 2021;81:1897-1903. [PMID: 34727332 PMCID: PMC8578114 DOI: 10.1007/s40265-021-01629-4] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
2
Goncalves J, Magro F, Danese S, Lakatos PL, Ben-Horin S. Editorial: antigenic response to CT-P13 and infliximab originator in IBD shows similar epitope recognition-evidence from basic science supports safe switching to biosimilars. Authors' reply. Aliment Pharmacol Ther 2018;48:575-576. [PMID: 30156326 DOI: 10.1111/apt.14860] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/08/2022]
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA